Online inquiry

IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15286MR)

This product GTTS-WQ15286MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Glioma Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ15286MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1310MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-700
GTTS-WQ6952MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ7065MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ15618MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA VAY-736
GTTS-WQ14356MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG7716
GTTS-WQ5156MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ242MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ1220MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABR-217620
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW